Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer — Stella

Recruiting

Back to Metastatic Castration-resistant Prostate Cancer (CRPC) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect, Madison, Wisconsin

Key details

Phase

Early testing

Sponsor

TechnoGenesys, Inc.

Collaborators

National Cancer Institute (NCI), Washington University School of Medicine

Enrollment target

~40 participants

Started

March 2026

Primary completion

December 2027

Age range

18 Years and older

Sex

Male only

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov